Join the club for FREE to access the whole archive and other member benefits.

National Resilience will collaborate with Mayo's Center for Regenerative Medicine

15-Aug-2022

Key points from article :

Mayo Clinic today announced a strategic collaboration with National Resilience Inc. in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions. 

The focus will be on therapies derived from human sources known as biologics — cells, blood, enzymes, tissues, genes or genetically engineered cells — for use in medicines.

"Mayo is making significant investments in facilities ... create thriving biotherapeutic companies," says Julie Allickson director of Mayo clinics.

The collaboration has these areas of focus:

  1. Process development expertise to advance Mayo Clinic biotherapeutics.
  2. Working together to attract biotech companies interested in sponsoring clinical trials at Mayo Clinic for novel regenerative biotherapeutics.
  3. Providing cell and gene products needed for biomanufacturing early-stage therapeutics.
  4. Analytical testing and quality control required for manufacturing commercial grade biopharmaceuticals.

Mayo Clinic advance regenerative technologies from discovery science to early phase clinical trials

Mentioned in this article:

Click on resource name for more details.

Julie Allickson

Director of Mayo Clinic's Center for Regenerative Medicine

Mayo Clinic

Non-profit American academic medical center focused on health care, education, and research

National Resilience will collaborate with Mayo's Center for Regenerative Medicine